SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
-
Published:2023-03-18
Issue:1
Volume:8
Page:
-
ISSN:2059-0105
-
Container-title:npj Vaccines
-
language:en
-
Short-container-title:npj Vaccines
Author:
Shrivastava ShikhaORCID, Carmen Joshua M., Lu Zhongyan, Basu Shraddha, Sankhala Rajeshwer S., Chen Wei-HungORCID, Nguyen PhuongORCID, Chang William C.ORCID, King JocelynORCID, Corbitt Courtney, Mayer SandraORCID, Bolton Jessica S., Anderson AlexanderORCID, Swafford IsabellaORCID, Terriquez Guillermo D., Trinh Hung V.ORCID, Kim JiaeORCID, Jobe Ousman, Paquin-Proulx DominicORCID, Matyas Gary, R.ORCID, Gromowski Gregory D., Currier Jeffrey R., Bergmann-Leitner ElkeORCID, Modjarrad Kayvon, Michael Nelson L., Joyce M. GordonORCID, Malloy Allison M. W.ORCID, Rao MangalaORCID
Abstract
AbstractThis study demonstrates the impact of adjuvant on the development of T follicular helper (Tfh) and B cells, and their influence on antibody responses in mice vaccinated with SARS-CoV-2-spike-ferritin-nanoparticle (SpFN) adjuvanted with either Army Liposome Formulation containing QS-21 (SpFN + ALFQ) or Alhydrogel® (SpFN + AH). SpFN + ALFQ increased the size and frequency of germinal center (GC) B cells in the vaccine-draining lymph nodes and increased the frequency of antigen-specific naive B cells. A single vaccination with SpFN + ALFQ resulted in a higher frequency of IL-21-producing-spike-specific Tfh and GC B cells in the draining lymph nodes and spleen, S-2P protein-specific IgM and IgG antibodies, and elicitation of robust cross-neutralizing antibodies against SARS-CoV-2 variants as early as day 7, which was enhanced by a second vaccination. This was associated with the generation of high titer, high avidity binding antibodies. The third vaccination with SpFN + ALFQ elicited high levels of neutralizing antibodies against the Omicron variant. No cross-neutralizing antibodies against Omicron were induced with SpFN + AH. These findings highlight the importance of ALFQ in orchestrating early induction of antigen-specific Tfh and GC B cell responses and long-lived plasma cells in the bone marrow. The early engagement of S-2P specific naive B cells and high titer IgM antibodies shape the development of long-term neutralization breadth.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference47 articles.
1. Dagotto, G., Yu, J. & Barouch, D. H. Approaches and challenges in SARS-CoV-2 vaccine development. Cell Host Microbe 28, 364–370 (2020). 2. World Health Organization. COVID vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (2023). 3. Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: status report. Immunity 52, 583–589 (2020). 4. Poland, G. A., Ovsyannikova, I. G., Crooke, S. N. & Kennedy, R. B. SARS-CoV-2 vaccine development: current status. Mayo Clin. Proc. 95, 2172–2188 (2020). 5. Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|